Last reviewed · How we verify

Assorted Licensed Hand Sanitizer Grape 01 (Licensed influenza vaccine)

Pfizer · FDA-approved active Biologic Quality 55/100

The mechanism of action is not specified.

Pfizer's Assorted Licensed Hand Sanitizer Grape 01, despite its misleading name, is an influenza vaccine that holds a significant market position as one of the world's best-selling drugs. Its competitive advantage is not clearly defined due to the lack of specified mechanism and clinical trial data, but it faces strong competition from alternatives like Oseltamivir (Tamiflu) and Zanamivir (Relenza), which offer options for individuals with egg allergies. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader applicability and market reach. The pipeline outlook remains uncertain given the absence of ongoing clinical trials and the presence of established competitors in the influenza vaccine market.

At a glance

Generic nameLicensed influenza vaccine
Also known asInfluenza HA, Biken, and, Fluarix tetra
SponsorPfizer
Drug classvaccine
Targetunknown
ModalityBiologic
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Unfortunately, the provided information does not specify the mechanism of action of Pfizer's licensed influenza vaccine. This makes it difficult to understand how the vaccine works at a molecular level. Further research is needed to determine the exact mechanism of action.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: